San Francisco, Calif. (June 19, 2002) – A new analysis shows Actonel® (risedronate sodium tablets) reduced the risk of nonvertebral osteoporotic fractures by 74 percent within one year in ...
San Antonio, TX (September 20, 2002) – A new analysis of scientific data presented at today's meeting of the American Society for Bone and Mineral Research (ASBMR) showed that a 5 mg dose of Actonel® ...
Procter & Gamble and Sanofi-Aventis in U.S. Approval for New Actonel Dose CINCINNATI and BRIDGEWATER, N.J., April 17 -- On April 16, 2007, the U.S. Food and Drug Administration (FDA) approved a new ...
NEW YORK (Reuters Health) - The results of a new study suggest that Actonel (risedronate) provides greater fracture protection in the first year of therapy than does Fosamax (alendronate). Among ...
CHICAGO (Reuters) - The makers of osteoporosis drug Actonel are testing a program to reimburse an insurer for the cost of treating non-spinal bone fractures among women who take the prescription pill.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results